Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 8Genitourinary 5Thoracic 3Plasma cell 3Myeloid 3Breast 3Gynecologic 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 3Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Diphenhydramine × Plasma cell × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT01985126 2018-06-25

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Janssen Research & Development, LLC

Phase 2 Completed
124 enrolled 18 charts
Plasma cell

Multiple Myeloma

NCT00899847 2017-10-20

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Stanford University

Phase 2 Completed
9 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡